Dr. Konstantinou is an associate scientist at the Campbell Family Mental Health Research Institute at CAMH, an interventional psychiatrist at the Temerty Centre for Therapeutic Brain Intervention at CAMH, and an assistant professor in the Department of Psychiatry at the University of Toronto.
Dr. Konstantinou received his Medical Doctor (MD) degree from the Aristotle University of Thessaloniki and completed his Residency in Psychiatry at the National and Kapodistrian University of Athens. He subsequently undertook a Clinical and Research Fellowship in Brain Stimulation at CAMH, and holds a Master of Science (MSc) in Aging and Chronic Diseases Management from the Hellenic Open University and the University of Thessaly, Greece.
He has authored and co-authored several peer-reviewed publications in high-impact journals, including JAMA Psychiatry, Brain, Behavior and Immunity, Bipolar Disorders, Journal of Affective Disorders, General Hospital Psychiatry, and Neuropsychopharmacology, and has received multiple national and international research and conference awards. Dr. Konstantinou currently serves as Principal Investigator on CIHR-funded clinical trials and as Co-Investigator on additional CIHR-funded and externally funded projects focused on interventional psychiatry treatment modalities for treatment-resistant psychiatric disorders.
Areas of Research
Dr. Konstantinou's research focuses on developing optimized, personalized treatment protocols for patients with treatment-resistant psychiatric disorders. His work integrates expertise in brain stimulation therapies, including repetitive transcranial magnetic stimulation (rTMS) and electroconvulsive therapy (ECT), with emerging pharmacological approaches such as psilocybin-assisted therapy and ketamine.
A central focus of Dr. Konstantinou's research is the treatment of mood disorders across the lifespan, including treatment-resistant depression, bipolar disorder, and late-life depression. He currently leads two CIHR-funded Phase II clinical trials investigating adjunctive psilocybin for treatment-resistant depression and psilocybin-assisted therapy for treatment-resistant late-life depression.
Dr. Konstantinou also investigates psychoneuroimmunology and neuroprogression, with a focus on neuroinflammation and blood-brain barrier (BBB) integrity in psychiatric disorders. His research examines how immune dysregulation and BBB dysfunction contribute to psychiatric pathophysiology and treatment resistance, with the goal of identifying novel biomarkers and immunomodulatory therapeutic targets.
Publications
View Dr. Konstantinou's publications on PubMed.